{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-249055","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.285706+00:00","generated_at":"2026-06-10T06:20:57.007703+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aura Biosciences names new CMO/President of R&D and CTO; CMO Rich transitions to advisor","bullets":["J. Jill Hopkins appointed CMO and President of R&D, effective Oct 16, 2023; prior roles at Novartis, Gyroscope, Roche-Genentech.","Mark Plavsic appointed CTO; 30 years experience including Fate Therapeutics, Sanofi Genzyme, AstraZeneca.","Cadmus Rich resigns as CMO effective Oct 16; will serve as Senior Clinical Advisor through Nov 7, then consultant for 9 months.","Hopkins receives annual base salary of $525k, sign-on bonus up to $200k, and equity grants of 200k options and 135k RSUs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-249055","json":"https://secwatch.observer/filing/0001193125-23-249055.json","markdown":"https://secwatch.observer/filing/0001193125-23-249055.md","text":"https://secwatch.observer/filing/0001193125-23-249055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/0001193125-23-249055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/d479220d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:20:57.007703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf2e0545c0","claim":"J. Jill Hopkins was appointed as Chief Medical Officer and President of Research & Development at Aura Biosciences, Inc..","evidence_excerpt":"J. Jill Hopkins, M.D., will serve as the Company’s Chief Medical Officer and President of Research & Development, effective as of October 16, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312523249055/0001193125-23-249055-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer and President of Research & Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}